J. Patrick McGovren, Ph.D.
Dr. McGovren has a Ph.D. in Pharmaceutical Sciences and extensive pharmaceutical industry and start-up experience in the preclinical and clinical development of anticancer drugs.
was deeply involved in the discovery and/or development of 10 clinically evaluated antitumor drugs.
Pat was a key advocate for The Upjohn Company's successful in-licensing of irinotecan which was marketed as Camptosar™ Injection and became a significant colorectal cancer product with $500 MM per annum US sales.
laboratory career, Dr. McGovren
was responsible for screening and detailed evaluation of test compounds in mouse tumor models as well as the preclinical pharmacology and pharmacokinetics of lead compounds.
Later he worked as a clinical operations manager for phase IV/post-marketing studies, and then moved into Pharmacia's clinical pharmacology group.
has prepared IND and NDA preclinical and clinical pharmacology sections and participated in resolving numerous clinical pharmacology-related regulatory issues.